Terms: = Prostate cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Prognosis
2295 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients.
Zhao Y; Lu SM; Zhong B; Wang GC; Jia RP; Wang Q; Long JH
Medicine (Baltimore); 2024 Apr; 103(17):e37934. PubMed ID: 38669432
[TBL] [Abstract] [Full Text] [Related]
3. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
4. Risk factor analysis and nomogram construction in patients with distant metastatic prostate cancer at different PSA levels: a study based on the SEER database.
Li HD; Fan SQ; Qin F; Zhao ST; Kong SP; Ma JG
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2372-2386. PubMed ID: 38567600
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
6. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
7. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
8. [Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy（2024 edition）].
Chinese Prostate Cancer Consortium
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(0):285-295. PubMed ID: 38527740
[TBL] [Abstract] [Full Text] [Related]
9. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
10. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
11. [Role of Bone Scan Index (BSI) in the prognosis and Treatment Efficacy in Castration-Sensitive prostate cancer Patients with Bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract] [Full Text] [Related]
12. A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
Chen J; Yu F; He G; Hao W; Hu W
BMC Cancer; 2024 Feb; 24(1):254. PubMed ID: 38395827
[TBL] [Abstract] [Full Text] [Related]
13. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract] [Full Text] [Related]
14. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
[TBL] [Abstract] [Full Text] [Related]
15. Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.
Rao S; Verrill C; Cerundolo L; Alham NK; Kaya Z; O'Hanlon M; Hayes A; Lambert A; James M; Tullis IDC; Niederer J; Lovell S; Omer A; Lopez F; Leslie T; Buffa F; Bryant RJ; Lamb AD; Vojnovic B; Wedge DC; Mills IG; Woodcock DJ; Tomlinson I; Hamdy FC
Genome Med; 2024 Feb; 16(1):35. PubMed ID: 38374116
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Value of the Modeled prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant prostate cancer Treated With Taxanes in FIRSTANA.
Carrot A; Oudard S; Colomban O; Fizazi K; Maillet D; Sartor O; Freyer G; You B
JCO Clin Cancer Inform; 2024 Feb; 8():e2300208. PubMed ID: 38364191
[TBL] [Abstract] [Full Text] [Related]
17. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant prostate cancer.
Saylor PJ; Otani K; Balza R; Ukleja J; Pleskow H; Fisher R; Kusaka E; Otani YS; Badusi PO; Smith MR; Meneely E; Olivier K; Lowe AC; Toner M; Maheswaran S; Haber DA; Yeap BY; Lee RJ; Miyamoto DT
JCO Precis Oncol; 2024 Feb; 8():e2300230. PubMed ID: 38354328
[TBL] [Abstract] [Full Text] [Related]
18. [cancers: incidence and survival in metropolitan France].
De Brauer C; Bousquet PJ; Lafay L
Rev Prat; 2024 Jan; 74(1):30-35. PubMed ID: 38329248
[TBL] [Abstract] [Full Text] [Related]
19. Copy Number Gain in Androgen Receptors Predicts the Poor prognosis in Japanese Castration-resistant prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
20. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study.
De Angelis R; Demuru E; Baili P; Troussard X; Katalinic A; Chirlaque Lopez MD; Innos K; Santaquilani M; Blum M; Ventura L; Paapsi K; Galasso R; Guevara M; Randi G; Bettio M; Botta L; Guzzinati S; Dal Maso L; Rossi S;
Lancet Oncol; 2024 Mar; 25(3):293-307. PubMed ID: 38307102
[TBL] [Abstract] [Full Text] [Related]
[Next]
